[go: up one dir, main page]

AR055600A1 - Sales y polimorfos de un inhibidor de vegf-r - Google Patents

Sales y polimorfos de un inhibidor de vegf-r

Info

Publication number
AR055600A1
AR055600A1 ARP060103431A ARP060103431A AR055600A1 AR 055600 A1 AR055600 A1 AR 055600A1 AR P060103431 A ARP060103431 A AR P060103431A AR P060103431 A ARP060103431 A AR P060103431A AR 055600 A1 AR055600 A1 AR 055600A1
Authority
AR
Argentina
Prior art keywords
salts
polymorphes
vegf
inhibitor
refers
Prior art date
Application number
ARP060103431A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR055600A1 publication Critical patent/AR055600A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se refiere a sales y formas de base libre de N,2-dimetil-6-[7-(2-morfolinoetoxi)quinolin-4-iloxi]benzofuran-3-carboxamida. También se refiere a composiciones farmacéuticas de estas sales y formas de base libre y procedimientos para tratar trastornos tales como cáncer usando tales composiciones.
ARP060103431A 2005-08-08 2006-08-07 Sales y polimorfos de un inhibidor de vegf-r AR055600A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70633205P 2005-08-08 2005-08-08
US75018905P 2005-12-14 2005-12-14

Publications (1)

Publication Number Publication Date
AR055600A1 true AR055600A1 (es) 2007-08-29

Family

ID=37320417

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103431A AR055600A1 (es) 2005-08-08 2006-08-07 Sales y polimorfos de un inhibidor de vegf-r

Country Status (13)

Country Link
US (1) US7928226B2 (es)
EP (1) EP1915368A1 (es)
JP (1) JP4536688B2 (es)
KR (1) KR20080027923A (es)
AR (1) AR055600A1 (es)
AU (1) AU2006277742B2 (es)
BR (1) BRPI0614115A2 (es)
CA (1) CA2615760A1 (es)
IL (1) IL188851A0 (es)
MX (1) MX2008001838A (es)
RU (1) RU2369607C1 (es)
TW (1) TW200738689A (es)
WO (1) WO2007017740A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006277742B2 (en) 2005-08-08 2010-08-26 Pfizer Inc. Salts and polymorphs of a VEGF-R inhibitor
CL2008000070A1 (es) * 2007-01-17 2008-07-25 Lg Life Sciences Ltd Monosal del acido maleico (3-[({1-[(2-amino-9h-purin-9-il)metil]ciclopropil}oxi)metil]-8,8-dimetil-3,7-dioxo-2,4,6-trioxa-3 lambda 5-fosfanon-1-il-pivalato; composicion farmaceutica que comprende a dicha monosal; y uso para el tratamiento del virus h
US8211911B2 (en) 2008-08-19 2012-07-03 Guoqing Paul Chen Compounds as kinase inhibitors
CA2770545C (en) * 2009-08-21 2015-11-03 F. Hoffmann-La Roche Ag Use of a bis-maleic anhydride cross-linking agent for fixation of a cell or tissue sample
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2138498C1 (ru) * 1994-07-22 1999-09-27 Бык Гульден Ломберг Хемише Фабрик Гмбх Дигидробензофураны, способ их получения и фармацевтическая композиция на их основе
WO1999032450A1 (en) * 1997-12-22 1999-07-01 Pharmacia & Upjohn Company 4-hydroxyquinoline-3-carboxamides and hydrazides as antiviral agents
ES2211175T3 (es) 1998-09-29 2004-07-01 Wyeth Holdings Corporation Inhibidores de proteinas de tipo tirosina quinasas a base de 3-cianoquinolinas sustituidas.
CA2393265A1 (en) * 1999-12-03 2001-06-07 Kyoto Pharmaceutical Industries, Ltd. Novel heterocyclic compounds and salts thereof and medicinal use of the same
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
EP1313726A1 (en) 2000-08-09 2003-05-28 AstraZeneca AB Quinoline derivatives having vegf inhibiting activity
WO2003074529A2 (en) 2002-03-01 2003-09-12 Pfizer Inc. iNDOLYL-UREA DERIVATIVES OF THIENOPYRIDINES USEFUL AS ANTI-ANGIOGENIC AGENTS
GEP20084572B (en) * 2003-12-23 2008-12-25 Pfizer Novel quinoline derivatives
US8091987B2 (en) 2005-07-07 2012-01-10 Xaar Plc Ink jet print head with improved reliability
AU2006277742B2 (en) 2005-08-08 2010-08-26 Pfizer Inc. Salts and polymorphs of a VEGF-R inhibitor

Also Published As

Publication number Publication date
US20090048254A1 (en) 2009-02-19
JP4536688B2 (ja) 2010-09-01
MX2008001838A (es) 2008-04-09
TW200738689A (en) 2007-10-16
RU2369607C1 (ru) 2009-10-10
JP2007045822A (ja) 2007-02-22
CA2615760A1 (en) 2007-02-15
US7928226B2 (en) 2011-04-19
BRPI0614115A2 (pt) 2011-03-09
KR20080027923A (ko) 2008-03-28
EP1915368A1 (en) 2008-04-30
RU2008104776A (ru) 2009-08-20
WO2007017740A1 (en) 2007-02-15
AU2006277742A1 (en) 2007-02-15
AU2006277742B2 (en) 2010-08-26
IL188851A0 (en) 2008-04-13

Similar Documents

Publication Publication Date Title
CY1124311T1 (el) Παρεμποδιστες dna-pk
EA201490567A1 (ru) Новые бициклические производные дигидрохинолин-2-она
ECSP10010245A (es) Peptidil nitrilos y uso de los mismos como inhibidores de dipeptidil peptidasa i
CR20180339A (es) INHIBIDORES DE PIRAZOLIL QUINAZOLINA CINASA (Divisional 2012-0576)
UY30600A1 (es) Compuestos novedosos
DOP2010000134A (es) Algunos derivados de 2-pirazinona como inhibidores de elastasa de los neutrofilos
CR10782A (es) Compuestos para inhibir la progresion mitotica
EA200971051A1 (ru) Ингибиторы p70 s6 киназы
CU20110204A7 (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
MX381849B (es) Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y métodos para su uso.
MX2013010969A (es) Ciclopropilaminas como inhibidores de desmetilasa 1 especifica de lisina.
SMT201300109B (it) Imidazopiridazincarbonitrili utili come inibitori di chinasi
ECSP099378A (es) Compuestos y composiciones como inhibidores de la proteina quinasa
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
UY31048A1 (es) Nuevos compuestos de pirimidina y usos de los mismos
BR112014030655A8 (pt) Compostos inibidores de pirimidinil tirosina quinase, e composição farmacêutica que os compreende
UY28745A1 (es) Nuevos compuestos
EA201490846A1 (ru) Новые производные арилхинолина
CR10766A (es) Inhibidores de metaloproteasa derivados de heterociclicos
EA200800546A1 (ru) Бензимидазолтиофеновые соединения в качестве ингибиторов polo-подобных киназ (plk)
CO6630193A2 (es) Inhibidores de la actividad de la proteína tirosina quinasa seleccionada
CL2011002911A1 (es) Compuestos derivados de benzamidas, inhibidores de serina proteasa; composición farmacéutica; uso del compuesto para tratar cáncer.
CR20140553A (es) Compuestos de fenoxietil piperidina
CR20110630A (es) Compuestos carboxamida y su uso como inhibidores de calpaína
CL2011002792A1 (es) Compuestos derivados de metoxifenil furan-3-(2h)-ona, inhibidores de fosfodiesterasa 10 (pde10); composicion farmaceutica que comprende a uno de los compuestos; y uso de la composicion farmaceutica en la preparacion de medicamentos para tratar trastornos de la alimentacion, obesidad, juego compulsivo, narcolepsia, entre otros.

Legal Events

Date Code Title Description
FB Suspension of granting procedure